Adoptive Cell Therapy
- Chimeric antigen receptor (CAR) T-cell therapy - Adoptive cell therapies like CAR-T involve collection of immune cells from a patient followed by ex vivo manipulation and/or expansion and reinfusion, and are the foundations of immuno-oncology today after showing success in the treatment of hematologic malignancies (MSD, Luminex, PCR, Flow Cytometry, ELISpot)
- Customized, specific assessment of hematologic malignancies.
- Platforms for immunoassay ligand binding assays
- Detection/quantification of gene expressions performed by qPCR.
- Vector copy number (VCN)
- ELISPOT analysis is for the measurement of specific T- or B cell responses.
- Flow cytometry for analysis of cellular targets including T cell activation
Additional genomics capabilities for clinical immunotherapy studies:
- Predictive biomarker assays (whole exome or RNA sequencing)
- qPCR or microarray-based RNA expression assays
- qPCR and ddPCR for replication-competent lentivirus (RCL) and replication-competent retrovirus (RCR) testing, and measuring gene persistence
- Gene expression profiles for detecting and characterizing mutations/biomarkers in cancer cells
- Comprehensive targeted NGS panels or tumor profiling assays to detect known and emerging biomarkers, and measure tumor mutational burden